Payment overview · 2025
General Payments
$61.43
3 reported records · 3 companies
Healthcare provider profile · identity verified
John Tibble, D.O
Allopathic & Osteopathic Physicians|Family Medicine · CHICAGO HEIGHTS, IL · NPI 1376960542
Verified facts
What the public records show
CMS Open Payments records show John Tibble, D.O received $61.43 in general payments during 2025 across 3 reported records.
Abbott Laboratories accounted for 37.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.21 | 37.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.09 | 32.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.13 | 29.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $61.43 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 64 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 501 | 171 |
| Amlodipine Besylate | Amlodipine Besylate | 356 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 223 | 68 |
| Lisinopril | Lisinopril | 218 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 217 | 67 |
| Losartan Potassium | Losartan Potassium | 196 | 56 |
| Metformin Hcl | Metformin Hcl | 184 | 55 |
| Gabapentin | Gabapentin | 173 | 68 |
| Montelukast Sodium | Montelukast Sodium | 169 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 155 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 48 |
| Omeprazole | Omeprazole | 129 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 120 | 54 |
| Allopurinol | Allopurinol | 111 | 32 |
| Furosemide | Furosemide | 110 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 41 |
| Jardiance | Empagliflozin | 92 | 29 |
| Carvedilol | Carvedilol | 90 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 26 |
| Meloxicam | Meloxicam | 83 | 30 |
| Metformin Hcl Er | Metformin Hcl | 83 | 28 |
| Potassium Chloride | Potassium Chloride | 83 | 34 |
| Alendronate Sodium | Alendronate Sodium | 81 | 22 |
| Eliquis | Apixaban | 71 | 23 |
| Simvastatin | Simvastatin | 71 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 22 |
| Ozempic | Semaglutide | 64 | 17 |
| Ezetimibe | Ezetimibe | 63 | 25 |
| Famotidine | Famotidine | 59 | 26 |
| Mounjaro | Tirzepatide | 55 | 13 |
| Spironolactone | Spironolactone | 51 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 12 |
| Alprazolam | Alprazolam | 47 | 16 |
| Glipizide Er | Glipizide | 47 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 16 |
| Farxiga | Dapagliflozin Propanediol | 46 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 17 |
| Sertraline Hcl | Sertraline Hcl | 43 | 14 |
| Lovastatin | Lovastatin | 42 | 13 |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 40 | suppressed |
| Ibuprofen | Ibuprofen | 40 | 19 |
| Prednisone | Prednisone | 40 | 33 |
| Trazodone Hcl | Trazodone Hcl | 40 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 20 |
| Glipizide | Glipizide | 38 | suppressed |
| Klor-Con M20 | Potassium Chloride | 38 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 38 | 11 |
| Glimepiride | Glimepiride | 36 | 14 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | 12 |
| Bupropion Xl | Bupropion Hcl | 32 | 14 |
| Naproxen | Naproxen | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 26 |
| Januvia | Sitagliptin Phosphate | 29 | 11 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 15 |
| Rybelsus | Semaglutide | 26 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Folic Acid | Folic Acid | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | 12 |
| Pregabalin | Pregabalin | 22 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | 13 |
| Methylprednisolone | Methylprednisolone | 20 | 20 |
| Tradjenta | Linagliptin | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 11 |
| Mupirocin | Mupirocin | 15 | 14 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | 13 |
| Colchicine | Colchicine | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Brilinta | Ticagrelor | 12 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 12 | suppressed |
| Dilantin | Phenytoin | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $61.43 · 3 records | Abbott Laboratories | BREZTRI, FREESTYLE LIBRE 3, Ozempic, Rybelsus | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error